Cott Beverages, Inc., a subsidiary of Cott Corporation, the world’s largest private label beverage company, and ChromaDex Inc. announced today that the two companies have entered into a licensing and supply agreement for the joint development of a clinically-backed, proprietary ingredient blend to serve the food & beverage, nutraceutical, and cosmetic markets.
“This agreement provides Cott access to ChromaDex’s pTeroPure® platform and establishes a relationship with a science-based leader in the nutraceutical industry,” remarked Doug Lynch, VP Business Development of the Star PhytoNutrients division of Cott. “We are excited to partner with ChromaDex, a name synonymous with both quality and science, and license its technology as part of our commitment to offering novel, best-in-class ingredients to our customers.”
“For ChromaDex, this agreement represents a great opportunity to license our growing portfolio of intellectual property to a recognized market leader in the consumer goods industry,” ChromaDex President Bill Spengler commented. “Cott’s market presence, distribution strength, consumer experience, and commitment to products with enhanced functionality and health benefits make it an exceptional partner as we continue to commercialize our pipeline of technology.”
About Star PhytoNutrients
The Star PhytoNutrients division of Cott Beverages Inc., a subsidiary of Cott Corporation (cott.com), develops and markets value-added botanical, fruit, antioxidant and highly functional ingredients, specializing in juice concentrates, fruit powders, and fruit extracts for use in food, beverages, nutraceuticals and cosmeceuticals. With a full line of ingredients derived from cranberries, the number one botanical ingredient in North America, Star PhytoNutrients has developed proprietary technologies for enhanced product functionality. For more information, please contact Douglas Lynch or Richard Star at 716-366-6100, or visit the website.
ChromaDex (chromadex.com) is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has an impressive pipeline of new ingredients, including its pTeroPure® pterostilbene for which it has worldwide, exclusive patent rights.
pTeroPure® (pteropure.com) is an ultra-pure formulation of pterostilbene, a compound found in blueberries and demonstrated to have multiple health benefits. pTeroPure® was recently named the 2010 North American Most Promising Ingredient of the Year by the prestigious independent research company, Frost & Sullivan. The first human clinical research study on pTeroPure is being conducted at the University of Mississippi Medical Center to evaluate the compound in patients with lipid (cholesterol) disorders. pTeroPure® is incorporated in several nutraceutical brands available at retailers nationwide. Capitalizing on the diverse potential applications of the product, ChromaDex is also developing pTeroPure for the skincare and pharmaceutical markets. For more information about pTeroPure, visit the webstie or call 949-600-9694.
ChromaDex Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Inquiries:
Liviakis Financial Communications, Inc.
John M. Liviakis, President
P: 415-389-4670 / E: John[.]Liviakis.com.